## **Appendix 4E**

## Cochlear Limited ACN 002 618 073 Preliminary Final Report As at 30 June 2025

## Results for announcement to the market

|  |    | Movement from 30 June 2024 |    |                 |
|--|----|----------------------------|----|-----------------|
| Sales Revenue <sup>1</sup>   | ир | 4%                         | to | A\$m<br>2,355.8 |
| Total Revenue  | up | 5%                         | to | 2,343.1         |
| Earnings before interest and taxes (EBIT)                          | up | 9%                         | to | 517.8           |
| Net profit for the period attributable to shareholders             | up | 9%                         | to | 388.9           |
| Underlying net profit for the period <sup>2</sup>                  | up | 1%                         | to | 391.6           |
| Basic earnings per share (cents)                                   | up | 9%                         | to | 594.3           |
| Underlying basic earnings per share (cents) <sup>2</sup>           | up | 1%                         | to | 598.4           |
| Dividend (dollars)   | up | 5%                         | to | \$4.30          |
|  |    |                            |    |                 |
| Net tangible assets per share at 30 June 2025 (cents) <sup>3</sup> | up | 4%                         | to | 2,216.5         |
| Net tangible assets per share at 30 June 2024 (cents)              |    |                            |    | 2,121.6         |
|  |    |                            |    |                 |

| Dividends  | Amount per security       | Franked amount per security <sup>4</sup> | Conduit foreign income per security <sup>4</sup> |  |  |
|--|---------------------------|--|--|--|--|
| Final dividend per share payable (dollars)               | \$2.15                    | \$1.83                                   | \$0.32   |  |  |
| Interim dividend per share paid (dollars)                | \$2.15                    | \$1.72                                   | \$0.43   |  |  |
| Total  | \$4.30                    | \$3.55                                   | \$0.75   |  |  |
| Previous corresponding financial year:                   |                           |  |  |  |  |
| Final dividend per share paid (dollars)                  | \$2.10                    | \$1.68                                   | \$0.42   |  |  |
| Interim dividend per share paid (dollars)                | \$2.00                    | \$1.40                                   | \$0.30   |  |  |
| Total  | \$4.10                    | \$3.08                                   | \$0.72   |  |  |
| Record date for determining entitlements to the dividend |                           | 19 September 2025                        |  |  |  |
| Dividend payment date                                    |                           | 13 October 2025                          |  |  |  |
| No dividend reinvestment plans were in operation         | during or since the year- | end.                                     |  |  |  |

Additional Appendix 4E disclosure requirements can be found in the 30 June 2025 Annual Financial Statements lodged with this document. This report is based on the 30 June 2025 Annual Financial Statements which have been audited by KPMG. The Independent Audit Report is included in the 30 June 2025 Annual Financial Statements.

<sup>&</sup>lt;sup>1</sup> Sales revenue is the primary revenue reporting measure used by Cochlear for the purpose of assessing revenue performance of the Consolidated Entity. It represents total revenue excluding foreign exchange contract gains/losses on hedged sales.

 $<sup>^{\</sup>rm 2}\,\mbox{Excluding}$  one-off and non-recurring items.

<sup>&</sup>lt;sup>3</sup> Net tangible assets are net assets less intangible assets.

 $<sup>^{\</sup>rm 4}\,\text{Rounded}$  to two decimal places